Assertio Holdings to Be Acquired by Garda Therapeutics in a $125.1 Million Deal

Key Takeaways

• Garda offers $18 cash per Assertio share, 2.23% discount
• Deal values Assertio at $125.1 million, 7.57× EBITDA
• Assertio sells non‑Resolvedon assets to Cosette for $35 million upfront
• Transaction includes a contingent value right tied to Sprix milestones
• Closing expected Q2 2026 after 20‑day window‑shop period

Pulse Analysis

Garda Therapeutics’ $125.1 million acquisition of Assertio Holdings marks a strategic push into broader specialty‑pharma territories beyond its core oncology focus. By paying $18 per share in cash—a modest 2.23% discount to the market price—Garda secures a portfolio that spans neurology, hospital care, and pain management. The valuation at 7.57 times EBITDA aligns with recent mid‑market pharma deals, suggesting a disciplined approach to pricing while the inclusion of a contingent value right (CVR) tied to Sprix milestones adds upside potential for shareholders if the product meets future performance thresholds.

The transaction also features a parallel asset divestiture: Assertio will offload its non‑Resolvedon products to Cosette Pharmaceuticals for an upfront $35 million, with further milestone‑based payments. This move cleanses Assertio’s balance sheet, allowing Garda to focus on high‑growth, higher‑margin assets while retaining cash flow from legacy products. For Garda, the acquisition bolsters its pipeline with established drugs for migraine, rheumatoid arthritis, and acute pain, creating cross‑selling opportunities and operational synergies with its existing oncology portfolio. The CVR structure reflects a common trend where buyers hedge against regulatory or commercial risk while offering sellers upside participation.

Industry observers see this deal as part of a broader consolidation wave among mid‑size specialty drug companies seeking scale to navigate rising development costs and regulatory scrutiny. Shareholders benefit from immediate cash proceeds and the prospect of future CVR payouts, while the combined entity is better positioned to negotiate with payers and expand market reach. The deal’s Q2 2026 closing timeline, coupled with a 20‑day window‑shop period, provides a clear roadmap for integration, setting a precedent for similar transactions in the evolving pharmaceutical landscape.